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Abstract
Background: The World Health Organization (WHO) has set ambitious targets for the elimination of onchocerciasis
by 2020–2025 through mass ivermectin treatment. Two different mathematical models have assessed the feasibility
of reaching this goal for different settings and treatment scenarios, namely the individual-based microsimulation
model ONCHOSIM and the population-based deterministic model EPIONCHO. In this study, we harmonize some
crucial assumptions and compare model predictions on common outputs.
Methods: Using a range of initial endemicity levels and treatment scenarios, we compared the models with respect
to the following outcomes: 1) model-predicted trends in microfilarial (mf) prevalence and mean mf intensity during
25 years of (annual or biannual) mass ivermectin treatment; 2) treatment duration needed to bring mf prevalence
below a provisional operational threshold for treatment interruption (pOTTIS, i.e. 1.4 %), and 3) treatment duration
needed to drive the parasite population to local elimination, even in the absence of further interventions. Local
elimination was judged by stochastic fade-out in ONCHOSIM and by reaching transmission breakpoints in
EPIONCHO.
Results: ONCHOSIM and EPIONCHO both predicted that in mesoendemic areas the pOTTIS can be reached with
annual treatment, but that this strategy may be insufficient in very highly hyperendemic areas or would require
prolonged continuation of treatment. For the lower endemicity levels explored, ONCHOSIM predicted that the time
needed to reach the pOTTIS is longer than that needed to drive the parasite population to elimination, whereas for
the higher endemicity levels the opposite was true. In EPIONCHO, the pOTTIS was reached consistently sooner than
the breakpoint.
Conclusions: The operational thresholds proposed by APOC may have to be adjusted to adequately reflect differences
in pre-control endemicities. Further comparative modelling work will be conducted to better understand the main
causes of differences in model-predicted trends. This is a pre-requisite for guiding elimination programmes in Africa and
refining operational criteria for stopping mass treatment.
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Background
Human onchocerciasis, a neglected tropical disease (NTD),
is a vector-borne filarial infection caused by Onchocerca
volvulus. The infection can lead to skin disease, visual
impairment and eventually blindness. It occurs primarily in
tropical sub-Saharan Africa (99 % of cases), but some foci
also exist in Yemen and Latin America. Over the past de-
cades, the overall disease burden of onchocerciasis has been
greatly reduced thanks to the implementation of large-scale
control programmes, namely, the Onchocerciasis Con-
trol Programme in West Africa (OCP, 1974–2002), the
African Programme for Onchocerciasis Control (APOC,
1995–2015) and the Onchocerciasis Elimination Program
for the Americas (OEPA, 1991-present). In the first dec-
ade of the OCP, vector control interventions (aimed at the
immature stages of the Simulium vectors) were used to
interrupt transmission, but the current mainstay of con-
trol is annual or biannual mass treatment with ivermectin.
OEPA has successfully interrupted transmission in most
foci in the Americas through 6- or 3-monthly ivermectin
mass treatment [1–6]. Success was also reported in several
African foci with annual or biannual ivermectin mass
treatment [7, 8] and other areas also seem to move to-
wards elimination [9], although there are also reports of
ongoing transmission in spite of prolonged ivermectin
mass treatment [10, 11]. In view of this evidence, APOC
decided to target elimination where feasible [12]. The
World Health Organization (WHO) set ambitious targets
for the elimination of onchocerciasis, which is to be
achieved by 2015 in the Americas and Yemen, by 2020 in
selected African countries, and by 2025 in 80 % of African
countries [13, 14]. There is broad international commit-
ment towards these goals, expressed through the adoption
of World Health Assembly Resolution on Neglected Trop-
ical Diseases (WHA66.12) and the endorsement of the
London Declaration on Neglected Tropical Diseases 2012
by pharmaceutical companies, donors, endemic country
governments and non-governmental organizations in-
volved in NTD control [15].
While past successes provide reason for optimism, an
important question remains regarding where and when
elimination can be achieved, and whether treatment strat-
egies need to be adjusted to achieve the WHO targets.
Work is ongoing to estimate when mass treatment can
likely be stopped in different countries and sub-national
regions. Important factors to consider when estimating
elimination prospects include local transmission condi-
tions (e.g. the endemicity level at baseline in the core of
the transmission zone, vector competence, contiguity of a
transmission zone), the start year of treatment, treatment
frequency, achieved treatment coverage levels and compli-
ance patterns, and complicating factors such as Loa loa
co-endemicity, the occurrence of suboptimal responses, or
lack of infrastructure [16–18]. All these factors to some
extent influence the duration of mass treatment required
to achieve elimination.
Mathematical models of onchocerciasis transmission
and control provide useful tools with which to estimate
the required duration of mass treatment in different
settings. Two different models have been used to estimate
the required duration for various endemic settings and
treatment scenarios: the individual-based microsimulation
model, ONCHOSIM [19, 20] and the population-based de-
terministic model EPIONCHO [21–23]. Both models have
predicted that the required duration increases with higher
baseline endemicity and lower treatment coverage, and can
be shortened by about 30–40 % when treating biannually
instead of annually. Estimates of the required duration in
absolute terms have been more difficult to compare due
to a lack of harmonization of model assumptions, simu-
lated scenarios, and presentation of types of output.
In this paper, we present a comparative modelling study
to explore the level of agreement between the ONCHO-
SIM and EPIONCHO models in their projections of esti-
mated programme duration to achieve elimination. A set
of policy-relevant scenarios was simulated with both
models, after harmonizing a number of critical input
parameters. Congruent and disparate results are discussed
to understand factors contributing to similarities and di-
vergences. We also pinpoint areas where our knowledge
base about the parasite population biology and drug activ-
ity is insufficient and further research is needed.
Methods
Mathematical models
ONCHOSIM and EPIONCHO, which were developed in-
dependently, have been applied in several previous model-
ling studies (ONCHOSIM [19, 20, 24–26]; EPIONCHO
[21–23, 27–29]). A comparison of key features and key
model parameters is presented in Table 1 and Table 2.
There are many similarities, but the models also differ in
some important aspects, e.g. on the extent to which het-
erogeneities in the human population (e.g. in exposure to
blackfly bites) and density dependencies in various pro-
cesses are captured (e.g. in parasite establishment rate
within humans and excess mortality of infected flies). The
sections below provide a brief description of the models
and their main characteristics. A detailed comparison of
the two models and previously published predictions will
also be presented elsewhere (Basáñez et al: River blind-
ness: mathematical models for control and elimination,
unpublished results).
ONCHOSIM
Model background ONCHOSIM is an individual-based
model for simulating onchocerciasis transmission and con-
trol in a dynamic human population, based on the tech-
nique of stochastic microsimulation [30]. The underlying
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generalised modelling framework has formed the basis for
similar models for other helminthic diseases, including
lymphatic filariasis [31], schistosomiasis [32] and soil-
transmitted helminthiases (presented elsewhere in this
collection [33]).
The model simulates a dynamic human population, con-
sisting of a discrete number of individuals. The population
composition changes over time due to birth, aging and
death of individuals. Through exposure to bites of Simu-
lium damnosum vectors, humans are populated by worms
and microfilariae (mf); transmission of infection between
human individuals is simulated by means of one central
population of blackflies. The fly density is expressed in
terms of the average number of fly bites received per
(adult) man per year, which is assumed to be constant
over time with fixed seasonal variation during the year. At
each fly bite, infection may be transferred from human to
fly and vice versa. The model considers a non-linear rela-
tionship between the mf intensity in human skin (microfi-
laridermia) and the average number of infective stage (L3)
larvae that will develop, from L1 larvae, in flies after taking
a blood meal. The biting rate varies between individuals,
both randomly and as a function of host age and sex.
Therefore, the rate of acquisition of new, incoming worms
and the intensity of infection vary between individuals.
The relative contribution of different individuals to infec-
tion levels in the blackfly population varies in exactly the
same way. Only a small, random proportion of the L3 lar-
vae that are released during a bite will develop successfully
into an adult worm, defined by a parameter named as the
success ratio.
Before introducing an intervention in the simulation, a
burn-in period is included to allow infection levels to
reach a dynamic, endemic equilibrium. The equilibrium
infection levels can be adjusted by modifying assump-
tions on the average biting rate and, if opportune, expos-
ure heterogeneity among individuals. Mass ivermectin
treatment programmes are simulated by specifying the
timing of treatment and the therapeutic coverage (i.e.
the proportion of the total population taking treatment).
Table 1 Overview of the main characteristics of the ONCHOSIM and EPIONCHO models
Characteristics ONCHOSIM EPIONCHO
Basic model structure
Number and type of spatial
locations modelled
Single place Single place
Population-based or individual-
based
Individual-based regarding humans and worms Population-based
Way of representing infection in
hosts
Presence and density at individual level Mean density in population subgroups (e.g. age, sex,
treatment compliance group). Prevalence as a function
of mean density assuming an underlying negative
binomial distribution
Role of chance Stochastic Deterministic
Interventions considered in
previous publications
Mass treatment, selective treatment (test and treat),
vector control,
Mass treatment, vector control
Features included in the model
Human population
demographics
Birth and death rate dynamically modelled; age
and sex composition
Birth and death rate, age and sex composition
Heterogeneities in the human
population
Age, sex, life expectancy, level of exposure to blackflies,
compliance with MDA, efficacy of treatment
Age, sex, life expectancy, level of exposure to blackflies,
compliance with MDA
Blackfly population density Fixed input as annual biting rate (ABR); seasonal
monthly biting rates
Fixed input as ABR; seasonality in biting rates can be
included
Exposure to blackfly vectors Heterogeneous (dependent on age, sex, personal
attractiveness to blackflies)
Heterogeneous (dependent on age and sex)
Uptake of infection by blackfly
vectors
Varying non-linearly (density-dependent) with infection
intensity in human hosts
Varying non-linearly (density-dependent) with infection
intensity in human hosts
Infection in blackfly vectors Density (average L3 load per fly) Density (average L3 load per fly)
Excess mortality of infected flies No Yes
Parasite acquisition in humans Proportional to mean number of L3 larvae inoculated,
denoted by the success ratio
Non-linearly (density-dependent) related to rate of
exposure to L3 larvae
Infection in humans Density (immature or mature worms, mf per skin snip) Density (non-fertile and fertile worms, mf per mg
of skin)
Diagnostic outcomes Mf count sampling to relate model predictions to data Sampling process and diagnostic performance of skin
snipping not yet included
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The probability that a simulated individual participates in
mass treatment with ivermectin is governed by age and
sex (children under five years of age are not treated; a ran-
dom proportion of women of reproductive age is not
treated, assuming that they are pregnant or lactating), and
a lifelong compliance factor (the higher the factor, the
higher the probability that an individual participates in
any given treatment round). Furthermore, some individ-
uals never participate in treatment, because they are
chronically ill or because they may refuse treatment (these
individuals comprise the systematic non-compliers, 5 % of
the population in this study). Regarding ivermectin effi-
cacy, we assume the same working mechanism as in previ-
ous simulation studies [19, 24, 34]. Drug effects include a
microfilaricidal effect, a temporal embryostatic effect, and
an anti-macrofilarial cumulative effect that reduces mf
production by adult female worms with each treatment
dose. In this paper, we adopt a set of assumptions about
ivermectin efficacy from a recent publication [20] (termed
“assumption set 1” in the cited paper), which has been
shown to fit well to trends in skin mf levels as observed in
a community trial encompassing five consecutive annual
ivermectin treatments in Ghana [35, 36]. According to this
set of assumptions: i) the microfilaricidal efficacy of iver-
mectin is 100 % and it acts instantaneously upon adminis-
tration; ii) there is no macrofilaricidal effect; iii) the
embryostatic effect causes all female worms to temporarily
cease mf production, which then recovers gradually over
time and reaches maximum production capacity after an
average of 11 months; iv) the cumulative effect on female
worm fertility amounts to an average 35 % reduction per
treatment, with cumulative effects in worms repeatedly
exposed to ivermectin.
ONCHOSIM has been previously used to successfully
mimic observed longitudinal epidemiological data from
various locations [35–38], and has been used for policy
making in the West-African Onchocerciasis Control
Programme [19, 34]. Further, ONCHOSIM predictions fit
reasonably well to longitudinal data from villages along the
Gambia and Bakoye River basins in West Africa [20], where
15 to 17 years of annual and/or biannual ivermectin mass
treatment have led to elimination of onchocerciasis [7, 8].
More information is provided in the additional files.
Additional file 1 provides a formal mathematical descrip-
tion of the model, instructions on installing and running
the model, a complete overview of the probability distri-
butions, functional relationships, and parameter values
that are used for this study, and annotated input and out-
put files. Additional file 2 contains a zip file, which in-
cludes the computer simulation program itself (with the
JAVA program code embedded in it), batch files used to
run the model, PDF documentation of the XML input,
and example input and output files.
Model outputs ONCHOSIM keeps track of changes over
time in the infection status (number of immature and ma-
ture, male and female worms, and mf density per skin snip)
in human individuals, and of the mean infective load in the
blackfly populations. Output is obtained by simulating an
epidemiological survey, in which mf intensity is measured
for each individual as the mean mf count per skin snip (ss),
assuming that two snips are taken of about 2 mg each.
Measurement variation in mf counts is considered (de-
scribed by a Poisson distribution around the true mf dens-
ity) and mf counts may sometimes be false negative (with
the probability of false negatives decreasing with higher mf
Table 2 Parameter assumptions used for the comparisons presented in this paper
Assumption ONCHOSIM EPIONCHO
Life expectancy of adult
worms
10 years [38] 10 years [38]
Life expectancy of microfilariae 0.75 years [58] 1.25 years [59]
Distribution of worm survival
times
Weibull Exponential
Proportion of blood meals
taken by vectors on humans
0.96 [30] and expert opinion 0.96 (matched to ONCHOSIM)a
Macrofilaricidal effect of
ivermectin
Not included Not included
Microfilaricidal effect of
ivermectin
100 %, instantaneous upon administration [36] 98-99 % at 2 mo. post-treatment following [40]
Embryostatic effect of
ivermectin
All female worms temporarily stop producing mf
but resume production gradually, reaching maximum
production capacity 11 months post-treatment on
average [36]
Fertile worms exposed to ivermectin decrease their mf
production according to the dynamics presented in [40] and
would fully recover if further untreated
Cumulative effect on mf
production by adult worms
35 % reduction in the rate of mf production per dose,
on average [36].
35 % reduction in the rate of mf production per dose [36]a
aDifferent values were applied in previous publications, but for the current model comparison presented in this paper the assumptions were harmonized with
those in ONCHOSIM
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loads). Individual outputs are aggregated to obtain informa-
tion on the mf prevalence (proportion of all individuals
with a positive mf count in either of the two snips), arith-
metic mean of individuals’ mf counts per snip (per individ-
ual calculated as the mean of two skin snips), and the
geometric mean (calculated as exp [(Σ log (x +1))/n] - 1,
with x being the an individual’s mean mf count per skin
snip (as above) and n the number of individuals included).
These outputs are provided for the population as a whole
and stratified by age group and sex. In this paper, we always
present the mf prevalence in the population aged 5 years
and above. The community microfilarial load (CMFL) is
equal to the geometric mean mf load per snip in adults
aged ≥ 20 years [39].
EPIONCHO
Model background EPIONCHO is a deterministic on-
chocerciasis transmission model that describes the rate of
change with respect to time and host age (in both sexes)
of the mean number of fertile and non-fertile female adult
worms per host, the mean number of mf per milligram
(mg) of skin, and the mean number of L3 larvae per simu-
liid fly. Full mathematical details of EPIONCHO can be
found in Turner et al. [21] and Basáñez et al: River blind-
ness: mathematical models for control and elimination,
unpublished results. Briefly, the model is based on a
prototype presented by Basáñez and Boussinesq [27], ex-
tended to include age and sex structure of the host popu-
lation [28]; the population-level effects of a single [40] and
multiple treatments with ivermectin, and increased pro-
grammatic realism related to patterns of treatment cover-
age and systematic non-compliance [21]. Aligning with
ONCHOSIM and in accordance with empirical data [41],
we have assumed that 5 % of the population is systematic-
ally non-compliant with treatment.
The human demography reflects that of savannah areas
of northern Cameroon, where the prevailing O. volvulus–
Simulium damnosum sensu lato combinations (i.e. savannah
parasites–S. damnosum sensu stricto / S. sirbanum) are re-
sponsible for the most severe sequelae of onchocerciasis.
The age distribution is assumed stationary and the popu-
lation closed (i.e. no migration). The model captures
age- and sex-specific host exposure to blackfly bites,
reproducing observed pre-control age-mf (intensity) pro-
files in Cameroon; patterns also reported in forest areas of
Cameroon [42] and elsewhere in former OCP areas of
West Africa [39]. EPIONCHO reflects pre-control infec-
tion levels in a range of hypo-, meso-, hyper- and highly
hyperendemic onchocerciasis foci by varying the annual
biting rate (ABR, number of bites received per person per
year) of the simuliid vectors.
Model outputs The natural output of EPIONCHO is the
per host mean number of mf per mg of skin. Microfilarial
prevalence is determined by assuming a negative binomial
distribution of mf among hosts with overdispersion par-
ameter treated as a non-linear (hyperbolic) function of the
(modelled) mean [43], and fitted to (pre-control) data on
the prevalence and intensity of microfilaridermia in
Cameroon [27]. In these data, the prevalence and intensity
of microfilaridermia were measured by counting mf in
two skin snips per person (from the right and left iliac
crests), after 24 h incubation in saline. By assuming that
this parameterization holds in all population age groups,
EPIONCHO estimates: (a) mf prevalence in children
aged ≥ 5 years and (b) by Monte Carlo simulation, and
using an average weight of 1.7 mg per skin snip [44], the
community microfilarial load (CMFL, the geometric mean
intensity of mf per skin snip in people aged ≥ 20 years.
Additional files 3, 4 and 5 provide instructions for in-
stalling and running EPIONCHO, and the source C code
(EPIONCHO.c) and R script (EPIONCHO.R) needed to
run the simulations presented in this paper.
Design of the model comparison study
Simulated scenarios
In this paper, we present a comparative modelling study
to explore the level of agreement between the ONCHO-
SIM and EPIONCHO models regarding three different
outcomes. This was done for a range of pre-control en-
demicity levels, varying from mesoendemic to very highly
hyperendemic or holoendemic (mf prevalence in the
population aged ≥5 years ranging from 51 % to 91 %).
Treatment scenarios varied with respect to the achieved
treatment coverage (50 %, 65 % or 80 %) and treatment
frequency (annual, biannual). An overview of all scenarios
Table 3 Setting characteristics and treatment scenarios for simulations
Factors varied in the simulations: Values considered
Setting characteristics
Pre-control endemicity (mf prevalence in the population aged≥ 5 years)a 51 %, 62 %, 81 %, 87 %, 91 %
Treatment scenarios (treatment frequency and coverage constant over time)
Population coverage of mass treatment Coverage low (50 %), intermediate (65 %), or high (80 %)
Treatment frequency Annual or biannual
Duration of mass treatment Up to 25 years
aSee Table 4 for information regarding the corresponding biting rates and CMFL
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is provided in Table 3. By tuning the assumed biting rates,
both models were calibrated to the predefined levels of mf
prevalence in the population aged ≥5 years (as this is the
population group that typically participates in epidemio-
logical surveys). For ONCHOSIM, the epidemiological
settings are matched to the settings considered by Coffeng
et al. [20], where the inter-individual variation in exposure
to blackfly bites was low (see also Table 4 below). In this
paper, we provide additional model output for the same
simulated scenarios. EPIONCHO matched the pre-control
levels of mf prevalence, whereas the assumed annual biting
rates (partly influenced by the assumed proportion of hu-
man blood meals taken by the vectors) and the resulting
CMFL are not necessarily identical in the two models.
Outcomes on which the models are being compared
In past publications, ONCHOSIM provided predictions of
the treatment duration needed to drive the parasite popu-
lation irreversibly to local elimination as evaluated many
years post-treatment, while EPIONCHO focused on the
time needed to bring mf prevalence below a critical
threshold, measured just before what would be the next
treatment round [19–21, 23, 43]. This was chosen to re-
flect the provisional operational thresholds for treatment
interruption and commencement of surveillance proposed
by APOC in 2010. We now consider both outcomes, to
allow comparison with previous work and to understand
how the choice of endpoint influences the required dura-
tions. In addition, we will compare the models’ predicted
trends in infection indicators (prevalence and intensity of
microfilaridermia) during mass ivermectin treatment. This
is explained in more detail below.
Outcome 1: predicted trends in infection with skin
microfilariae during ivermectin mass treatment We
compared the models with respect to their predicted
trends in microfilarial infection over time during a 25-
year programme of annual mass ivermectin treatment,
assuming that 65 % of the total population is treated per
round. In particular, we looked at predicted trends in mf
prevalence among the population aged ≥5 years and the
arithmetic mean mf intensity in the whole population,
for each of the five baseline mf prevalence levels consid-
ered. The prevalence and intensity of mf were assessed
annually at the moments of treatment, just before the
scheduled treatment round. The dynamic changes in-
between treatment rounds are therefore not visualized.
For ONCHOSIM, we performed 150 repeated runs per
scenario all with the exact same inputs. After exclusion
of runs with extinction of infection during the burn-in
period (only at the lowest endemicity level, where this
occurs in about 10 % of simulation runs) we calculated
the average trend in mf prevalence. For EPIONCHO, in
accordance with the deterministic nature of the model,
only a single simulation was needed per scenario.
Outcome 2: treatment duration needed to achieve a
provision operational threshold for treatment inter-
ruption For each baseline mf prevalence and for the
different treatment scenarios considered, we determined
the minimum duration of mass treatment that would be
required to bring the mf prevalence as measured just be-
fore what would be the next treatment round below a
provisional Operational Threshold for Treatment Inter-
ruption followed by Surveillance (pOTTIS), as previously
reported and defined in [22]. The pOTTIS is based on the
working thresholds proposed by APOC in its conceptual
and operational framework for onchocerciasis elimination
with ivermectin treatment [12]. These thresholds are de-
fined (by APOC) as an mf prevalence of <5 % in all sur-
veyed villages and <1 % in 90 % of such villages, as well as
fewer than 0.5 infective larvae per 1000 examined flies
(which, given the probability that – near elimination – in-
fective flies will carry only one L3 larva, translates into
0.05 % infective flies). The APOC criteria involve a dual
threshold, to capture distribution of mf prevalence levels
in multiple communities in an area. APOC’s first criterion
(prevalence <5 % in all surveyed villages) suggests that
bringing prevalence below 5 % should be sufficient for
achieving elimination. The second criterion may serve to
verify that mass treatment was effectively implemented
throughout the area: if this 5 % threshold were reached
Table 4 Comparison of ONCHOSIM and EPIONCHO with respect to the annual biting rate and community microfilarial load (CMFL, the
geometric mean no. of mf per skin snip in those aged 20 years and above) that correspond to the pre-set value of mf prevalence in the
population aged ≥5 years matched by both models
Pre-set value of mf
prevalence in the 5+
population
ONCHOSIM EPIONCHO
ABR (bites / person / year) CMFL (mf/ss) ABR (bites / person / year) CMFL (mf/ss)
51 % 9,409 5.9 2,250 5.5
62 % 10,150 10.5 3,375 9.8
81 % 14,098 33.6 18,906 30.5
87 % 18,078 56.7 34,219 55.0
91 % 22,212 79.4 46,875 83.6
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even in the communities closest to breeding sites, then
considerably lower levels would be expected in most other
communities with less intense transmission. This defin-
ition has been rendered compatible with the closed popu-
lation structure of the two models under comparison by
defining a single threshold. Rather than using the upper
threshold of 5 %, which is still subject to uncertainty and
may lead to misinterpretation of the criteria, we have
chosen to use the weighted average of the upper and lower
thresholds: when the modelled mf prevalence falls to
<1.4 %, measured just before the next treatment round,
the pOTTIS has been achieved [22]. The pOTTIS is as-
sumed to refer to the mf prevalence in the population
aged ≥5 years rather than in the total population, because
children under 5 are generally excluded from field surveys
or strongly underrepresented.
To estimate the number of treatment rounds required
for achieving the pOTTIS, we simulated the respective
treatment scenarios (see below) for a maximum duration
of 25 years. Trends in mf prevalence were simulated as de-
scribed above for outcome 1, with mf prevalence mea-
sured at the moments of treatment (either annually or
biannually, always just before treatment). Treatment was
assumed to be no longer needed if the average mf preva-
lence dropped below the pOTTIS threshold. The required
duration in years is then either the minimum number of
annual treatments needed to reach the pOTTIS or the
number of biannual treatments multiplied by 0.5.
Outcome 3: the treatment duration that is needed to
drive the parasite population irreversibly to local
elimination The third outcome considered is the mini-
mum required treatment duration that is needed to drive
the parasite population irreversibly to local elimination, as
previously done with ONCHOSIM and described by
Coffeng et al. [20]. As laid out by the transmission break-
point theory for dioecious parasite species [45, 46], the
prevalence (or intensity) of infection does not need to be
reduced exactly to zero for mass treatment to be able to
stop. Below some epidemiological threshold, which de-
pends on transmission conditions, the probability that a
worm successfully reproduces and brings forth at least
one new reproducing worm falls below 1 so that transmis-
sion becomes unsustainable and the worm population will
gradually disappear for the scenario analysed.
With ONCHOSIM, the required duration of mass treat-
ment was estimated based on the eventual occurrence of
elimination in a simulation, 50 years after the last treat-
ment, allowing for stochastic fade-out or natural disappear-
ance. Because many processes simulated in ONCHOSIM
involve probabilities, repeated model simulations based on
the same assumptions will result in slightly different pre-
dictions because of stochastic variation. Therefore, with
ONCHOSIM, we estimated the probability of elimination
as the fraction of 1000 repeated simulations that result in
elimination. Elimination was defined as absence of infec-
tion 50 years after the last mass treatment, where infection
diagnosis was based on two skin snips per person (assum-
ing that the chance of finding zero mf-positive individuals
among all simulated individuals (~400) is negligible during
sustainable transmission). As in previous ONCHOSIM
publications, the required duration is the minimum num-
ber of treatment rounds that result in a probability of elim-
ination of ≥99 %.
Deterministic models sometimes allow analytical explor-
ation of breakpoints, e.g. in the absence of interventions or
by applying simplifying assumptions on the dynamical
responses elicited by interventions [45]. This is not feasible
with relatively more complex models such as EPIONCHO.
Therefore, for EPIONCHO we evaluated numerically
whether the breakpoint was reached by tracking the para-
site population long after cessation of the simulated inter-
vention. The implicit breakpoint and hence required
treatment duration to drive the parasite to elimination de-
pend on assumptions concerning the mating probability
(the probability that female worms are mated), which in
turn is influenced by the worm sex ratio, the sexual system
(monogamous or polygamous), and the distribution of
adult worms in the host population [47]. For the purposes
of this paper we have assumed a balanced sex ratio (1:1), a
system of polygamy [48], and a Poisson distribution of
adult worms in the human host population (assumed to
follow a negative binomial distribution in previous papers),
with male and female worms distributed together.
Availability of data and materials
Data and simulation software (EPIONCHO and ONCH-
OSIM) are made available or can be reproduced via the
additional files included in this paper. See the descrip-
tion of additional files below.
Results
The two models were calibrated to match the required
pre-control mf prevalence levels in the population aged
≥5 years by adjusting the annual biting rate. Table 4 shows
the biting rates that were used as well as the correspond-
ing mf prevalence and CMFL levels. The relationship
between annual biting rate and mf prevalence differs
somewhat between the models (Fig. 1). The biting rates in
ONCHOSIM varied from about 9 to 22 thousand to simu-
late the required levels of mf prevalence (50–90% in the
population aged ≥5 years), whereas in EPIONCHO the
biting rates covered a wider range, from about 2 to 47
thousand bites per person per year. The corresponding
predicted CMFL values (which were not matched by de-
sign) are comparable for the two models (Table 4).
Figure 2 compares the predicted trends in mf prevalence
in the population aged ≥5 years during a 25-year mass
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treatment programme where 65 % of the population is
treated annually with a single dose of ivermectin. Similarly,
Figure 3 compares predicted trends in the arithmetic
mean intensity of mf in the population (all ages) relative to
the pre-control (endemic equilibrium) level. EPIONCHO
predicts a fast initial decline in both mf prevalence and
mean mf count for all 5 endemic settings, but the decline
levels off and the two infection indicators tend to move
towards a new equilibrium. In ONCHOSIM, the initial de-
cline is less pronounced, but it does not level off as much.
Eventually, the infection indicators reach zero faster in
ONCHOSIM than in EPIONCHO. The difference be-
tween the two models is more pronounced for the mf
prevalence than for the mean mf intensity.
Table 5 summarises for both models the estimated re-
quired durations to achieve the pOTTIS and to drive the
parasite population to local elimination for all settings and
treatment scenarios. The same data are graphically repre-
sented in Fig. 4 to visualize the patterns in the results. The
EPIONCHO- and ONCHOSIM-predicted treatment dura-
tions for reaching the pOTTIS are pretty close for settings
with moderate baseline prevalence (51 or 62 % mf preva-
lence). Yet, EPIONCHO predicts a greater lengthening in
required treatment duration with increasing baseline en-
demicity than ONCHOSIM; also predictions for areas with
higher baseline endemicity levels (≥81 % mf prevalence)
are more divergent. ONCHOSIM predicts that pOTTIS
can still be reached by 20–25 rounds of annual mass treat-
ment, if coverage is high enough (80 % required in the
highest transmission settings) and that the required treat-
ment duration can be reduced by ~35 % if mass treatment
is provided biannually. EPIONCHO is more pessimistic,
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Fig. 1 Relationship between the annual biting rate (bites per person per year) and microfilarial (mf) prevalence in the population aged 5 years
and above in the two models
Fig. 2 Comparison of expected trends in microfilarial (mf) prevalence during mass treatment, as predicted by ONCHOSIM and EPIONCHO, for
settings with different baseline endemicity (mf prevalence in the population aged ≥ 5 years) assuming a coverage of 65 %
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suggesting that the pOTTIS cannot be achieved in settings
with baseline mf prevalence of 81 % or higher, not even
with 25 years of biannual treatment and 80 % coverage.
EPIONCHO is also more pessimistic than ONCHOSIM
about the possibility of driving the parasite population to
local elimination. EPIONCHO suggests that this will only
be achievable within 25 years for the setting with 51 %
baseline mf prevalence, and that this would require longer
continuation of mass treatment than required to achieve
the pOTTIS. ONCHOSIM suggests that local extinction
is achievable everywhere, although in settings with very
high baseline endemicity this might require biannual treat-
ment and/or high treatment coverage (80 %). For areas
with moderate baseline endemicity (51 % or 62% mf
prevalence), ONCHOSIM suggests that the required treat-
ment duration for driving the parasite population to local
elimination is shorter than that needed for achieving the
pOTTIS. The reverse was found in settings with the high-
est baseline mf prevalence.
Discussion
This paper presents for the first time a vis-à-vis compari-
son of the ONCHOSIM and EPIONCHO models. We
found that whilst EPIONCHO predicts a faster initial
decline in mf prevalence and intensity than ONCHO-
SIM, EPIONCHO is more pessimistic about the long-
term prospects of achieving the pOTTIS and local
elimination.
Harmonized input assumptions
For the purpose of the presented comparisons, we harmo-
nized some key assumptions which have previously been
identified as very influential on the duration of ivermectin
MDA programmes [21]. One critical assumption is the
magnitude and irreversibility of the effect of ivermectin on
fertility (production of live mf) by adult O. volvulus
females. By fitting ONCHOSIM to data on mf loads ob-
tained during an early community trial of annual ivermec-
tin treatment in Asubende, Ghana [35], Plaisier et al. [36]
had estimated a loss of mf production ranging from 22 to
40% per treatment round. A value of 35 % was recently
used in ONCHOSIM by Coffeng et al. [20], but a more
conservative value of 7 % (varied in a sensitivity analysis
from 1 to 30 %) had been used in EPIONCHO by Turner
et al. [22]. In this paper we have used the value of 35 %,
which has yielded a good qualitative match for both
models to the longitudinal parasitological data on mf loads
from the feasibility of elimination study conducted by
Diawara et al. [7] in some foci of Mali and Senegal [20].
A previous modelling study by Bottomley et al. [49]—who
fitted a model to data from a community trial of biannual
ivermectin treatment in Guatemala [44]—had reached the
conclusion that the effect of repeated ivermectin treatments
on mf production by adult worms was not cumulative.
Other studies, e.g. [50, 51], have reported that repeated
ivermectin doses may have deleterious effects on adult
worms, but the mechanisms and magnitude of such effects
remain poorly understood. Model predictions on required
treatment duration are also highly sensitive to this param-
eter, and both models therefore assumed a cumulative
effect. It remains, however, critical to better understand the
impact of ivermectin on the survival and reproduction (the
components of fitness) of O. volvulus, to improve our abil-
ity to accurately project the outcome of interventions and
to appreciate the potential evolutionary implications
of such interventions (e.g. selection pressure due to
treatment [16]).
The fraction of bites that a blackfly takes on humans
(assumed to be 0.96) is also a key parameter. By aligning it
between the two models, we brought together the annual
biting rates necessary to reproduce initial mf prevalence
values (Fig. 1). However, field studies on blood host choice
Fig. 3 Comparison of expected trends in arithmetic mean mf intensity during mass treatment, as predicted by ONCHOSIM and EPIONCHO, for
settings with different baseline endemicity (mf prevalence in the population aged 5 years and above) assuming a coverage of 65 %
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by onchocerciasis vectors [52] have indicated that the
human blood index may be variable among compo-
nent species of the S. damnosum s.l. complex, and this
information remains important when modelling trans-
mission in different epidemiological settings across
Africa, in particular to get an accurate reflection of
biting rates needed to produce different infection en-
demicity levels.
We also harmonized assumptions on the proportion of
the population that is systematically non-compliant with
treatment, a common parameter in both models. This was
done, because a core group of individuals who are
Table 5 Comparison of ONCHOSIM and EPIONCHO with respect to estimated duration of treatment that is needed to bring mf
prevalence below the provisional operational threshold for treatment interruption followed by commencement of surveillance
(pOTTIS) of 1.4 %, measured just before what would be the next treatment round, and the estimated duration of treatment needed
to drive the parasite population to local elimination in the absence of further treatment (allowing for the slow natural extinction in
the absence of further interventions)
Approximate initial mf
prevalence (%) in the
population aged≥
5 years
Coverage
(%)
Treatment duration needed to bring the 12-month
or 6-month post-treatment mf prevalence below
pOTTIS (years)
Treatment duration needed to drive the parasite
population irreversibly to extinction in the absence of
further treatment (years)
ONCHOSIM EPIONCHO ONCHOSIM EPIONCHO
Annual treatment
51 50 18 17 12 >25
65 14 15 8 23
80 12 12 6 21
62 50 21 24 14 >25
65 16 20 10 >25
80 14 17 8 >25
81 50 >25 >25 >25 >25
65 21 >25 18 >25
80 17 >25 15 >25
87 50 >25 >25 >25 >25
65 25 >25 >25 >25
80 20 >25 20 >25
91 50 >25 >25 >25 >25
65 >25 >25 >25 >25
80 23 >25 >25 >25
Biannual treatment
51 50 12.5 12 6 21
65 10 11 4.5 20
80 8 10 4 19.5
62 50 14 17 8.5 >25
65 11 16 6 >25
80 9.5 10 5 >25
81 50 18.5 >25 17 >25
65 13.5 >25 12 >25
80 12 >25 10 >25
87 50 22.5 >25 24 >25
65 15.5 >25 16.5 >25
80 13.5 >25 14 >25
91 50 >25 >25 >25 >25
65 17 >25 21 >25
80 14.5 >25 18 >25
Results are shown for different settings, varying with respect to the pre-control mf prevalence in the population aged ≥ 5 years, and for several treatment scenarios,
varying with respect to the treatment frequency and achieved coverage (defined as the percentage of people who receive treatment in the total population)
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untreated and remain infected, potentially provides a
source of onward transmission in the human host popula-
tion, as was also indicated by epidemiological observations
of lymphatic filariasis in Haiti, where continuing transmis-
sion was related to rates of systematic noncompliance
[53]. Harmonization of assumptions on systematic non-
compliance does not make the models completely compar-
able; differences remain in the distribution of treatments
over the remainder of the population because of the differ-
ent approaches to modelling compliance patterns. We
need to understand better how treatment compliance pat-
terns can best be modelled. More programmatic data on
patterns of individual compliance to inform the mathemat-
ical constructs used to model compliance are therefore
essential [54].
Predicted trends in infection during mass treatment
In spite of harmonized treatment efficacy assumptions,
EPIONCHO predicted a faster initial decline in mean mf
intensity and mf prevalence than ONCHOSIM. In the lon-
ger term, ONCHOSIM predicts that infection intensity
will decline to zero everywhere, while EPIONCHO sug-
gests that mf intensity may stabilizes at a level above zero.
The factors contributing to differences in long-term
predictions are discussed below. Here we discuss the fac-
tors that contribute to differences in the shorter-term
predictions.
The differences in the initial decline in mf intensity may
be explained by somewhat different assumptions regard-
ing the temporal dynamics of the microfilaricidal effect of
ivermectin as well as the rate of mf production by female
worms and mf lifespan, leading to different mf repopula-
tion rates in the period between treatments. This, how-
ever, does not fully explain the more marked differences
in predicted mf prevalence trends. The individual-based
model ONCHOSIM always predicts a relatively slow ini-
tial decline in prevalence, because treated individuals are
expected to remain mf positive for some time, albeit with
considerably lower mf loads. This is in line with observa-
tions from a study in Ghana, which showed that mf preva-
lence rapidly bounced back in the interval between
treatment rounds, nearly to pre-treatment levels, while
the bounce back in mean mf intensity is less pronounced
[35]. In EPIONCHO, mf prevalence is indirectly derived
from the predicted mean mf load, through a non-linear
prevalence–intensity relationship fitted to pre-control data
Fig. 4 Duration of mass ivermectin treatment in years that is needed to bring mf prevalence below the pOTTIS (red lines and symbols) or to
eventually reach local elimination (blue lines and symbols), for ONCHOSIM (left) and EPIONCHO (right) and for annual (top) and biannual treatment
(bottom). Dashed lines in each graph connect estimates obtained for different endemicity levels under the assumption that 65 % of the total
population is treated per round (coverage). The vertical bars indicate how the duration would change if the coverage was 50 % per round (triangles)
or 80 % (circles). To be able to differentiate the prediction intervals obtained for the different endpoints, the results are displayed slightly to the left or
right of the actual simulated baseline prevalence (+/− 0.6 %)
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[43]. In this relationship, low mf loads are associated with
similarly low mf prevalence levels. The relationship be-
tween the two indicators was assumed to remain un-
changed during mass treatment, for consistency with
previous EPIONCHO publications. This assumption will
have to be adjusted in future work, as the mf prevalence-
intensity is likely to be altered by mass treatment, due to
the direct microfilaricidal effect of treatment and the rela-
tively slow rate of mf repopulation. Quantification of the
post-treatment relationship, ideally using parasitological
data obtained during MDA programmes, is therefore an
imperative area of further investigation for EPIONCHO.
The model-predicted trends in infection prevalence and
intensity, as well as corresponding frequency distributions
of mf counts, should be compared against epidemiological
data on trends in mf prevalence and intensity during mass
ivermectin treatment. Such data are available from the
previously mentioned 5-year community intervention trial
on the impact of ivermectin mass treatment that was
carried out in a highly endemic setting in Ghana [35].
ONCHOSIM has been fitted to these data [36], and the
validity of EPIONCHO-predicted trends can be tested
against the same data. However, models should also be
tested with similar data from other endemic settings, cov-
ering a range of pre-control endemicity levels.
Required duration to reach the pOTTIS or to drive the
parasite population to local elimination
An important question for ongoing onchocerciasis elim-
ination programmes concerns the required duration of
mass treatment. We explored this on the basis of two
endpoints, namely 1) the duration of ivermectin mass
treatment required to reach a defined threshold of mf
prevalence below which treatment can be stopped (the
pOTTIS), and 2) the duration required to drive the para-
site locally to elimination, even without further interven-
tions. The first reflects operational criteria for deciding
when to stop interventions, although the critical threshold
remains to be validated. A limitation of the pOTTIS ap-
proach is the focal nature of onchocerciasis, whereby
communities with ongoing transmission may act as a
source of new infections for those communities where the
infection has been eliminated. It is noteworthy that nei-
ther EPIONCHO nor ONCHOSIM currently capture
spatial transmission processes that may couple transmis-
sion among geographically distinct foci. Hence, the elim-
ination projections should be interpreted as capturing the
likely outcome of interventions undertaken in circum-
scribed foci with negligible influx of extraneous infections.
Although predicted trends in infection during mass
treatment differ between the two models, estimates of the
required duration of annual treatment for achieving the
pOTTIS were comparable for settings with moderate
baseline mf prevalence (51–62 % mf prevalence). The
predictions for areas with higher baseline endemicity
levels became more pessimistic and divergent. ONCHO-
SIM suggests that reaching the pOTTIS would often still
be feasible, albeit with longer continuation of treatment,
higher coverage, or more frequent treatment. EPIONCHO,
however, suggests that even 25 years of biannual treatment
with 80 % coverage is not sufficient to achieve the pOTTIS.
This is reflected in the EPIONCHO-predicted trends in mf
intensity and prevalence, which tend to stabilize at a new
non-zero equilibrium after long-term mass treatment
(Figs. 2 and 3).
ONCHOSIM is also more optimistic than EPIONCHO
about the possibility of driving the parasite population to
local extinction. EPIONCHO suggests that the parasite
can only be driven to elimination in settings with moder-
ate baseline mf prevalence, although this would require
longer continuation of treatment than needed to achieve
the pOTTIS. ONCHOSIM suggests that the parasite
population would be driven to elimination even before the
pOTTIS is reached in settings with moderate baseline en-
demicity; elimination can also be achieved in settings with
higher baseline mf prevalence, although treatment will
have to be continued longer than needed for achieving the
pOTTIS. This suggests that the fixed operational elimin-
ation thresholds proposed by APOC may overestimate the
required duration for elimination in the former settings,
but underestimate it in the latter.
Long-term predictions on the time needed to reach the
pOTTIS or drive the parasite population to local elimin-
ation should be interpreted with caution for both models.
It will be difficult to validate the models’ predictions
regarding the time needed to drive the parasite locally to
elimination. Yet, empirical data may help to validate pre-
dicted durations for reaching the pOTTIS. In this respect,
useful data are available from a study performed in Mali
and Senegal, which provided the first evidence that oncho-
cerciasis can be eliminated in Africa through ivermectin
mass treatment [7, 8]. Baseline endemicity levels of these
regions reflect the lower range of values considered in this
study. Data from epidemiological monitoring of ongoing
elimination programmes in Africa (such as [9]) will also
be informative, in particular if baseline data are available
and the area is highlyendemic. Whether or not elimination
will really be feasible in very highly endemic areas, with ei-
ther annual or biannual treatment, remains an important
question.
Possible explanations for differences in required
durations for elimination
Several factors contribute to the longer treatment duration
required for achieving elimination in EPIONCHO com-
pared to ONCHOSIM, in spite of the faster initial drop in
mf prevalence and to a lesser extent intensity. Firstly,
EPIONCHO does not account for the possibility of chance
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elimination of the parasite population (stochastic fade-
out), which becomes increasingly likely at very low inten-
sities of infection, especially for small settings (villages)
with a couple of hundred inhabitants (as assumed by
ONCHOSIM). Secondly, the models differ with respect to
assumptions about density dependence in the various pro-
cesses involved in transmission dynamics (as indicated in
Table 1), which may also be important for elimination pros-
pects [45, 55]. In particular, EPIONCHO includes a (nega-
tive) density-dependent relationship between the annual
transmission potential and the parasite establishment rate;
ONCHOSIM does not capture this mechanism, which
makes the model more optimistic. Thirdly, the assumed
distribution of adult worm and microfilarial survival times
and assumptions regarding mf productivity in relation to
worm-age may play a role. EPIONCHO assumes an expo-
nential distribution of worm survival times with a long right
tail, implying that worm mortality rates are independent of
worm age (an implicit assumption of the exponential
model). ONCHOSIM assumes a Weibull distribution [38],
a more symmetrical distribution with the same mean sur-
vival time but a shorter right tail, implying age-dependency
of worm-mortality rates. Therefore, it takes considerably
longer for the parasite population to die out naturally in
EPIONCHO than in ONCHOSIM. In addition to this,
ONCHOSIM assumes that the mf production rate declines
in older worms, so that the relatively old worm population
remaining after long-term ivermectin mass treatment has a
relatively low mf production. Such a process is not consid-
ered by EPIONCHO. Lastly, the distribution of adult
worms among the human population will play a role again
through its influence on the mating probability. This as-
sumed distribution is explicit in EPIONCHO (in this paper
by using a Poisson distribution) and implicit in ONCHO-
SIM, driven by between-host heterogeneities in exposure
and compliance with treatment.
EPIONCHO and ONCHOSIM also differ considerably
in their assumptions regarding the life expectancy of
microfilariae, being 0.75 years in ONCHOSIM and
1.25 years in EPIONCHO (Table 2). This is unlikely to
have a strong influence on the projected programme dura-
tions, because (a) the potency of ivermectin against mf is
such that their natural life-span becomes much less rele-
vant and (b) the transmission breakpoint (and the chance
of stochastic fade-out) is much more influenced by the life
span of adult worms that have a life-expectancy an order
of magnitude greater than that of mf (about 10 years
versus 1 year). Yet, this difference may explain at least
partly—and in combination with the different modelled
density-dependent population processes—the markedly
different shapes in the relationship between the fitted an-
nual biting rate and the pre-set endemic mf prevalence
presented in Fig. 1. In EPIONCHO, on account of the lon-
ger life expectancy of mf, and the greater parasite
establishment rate at low levels of transmission intensity,
a lower biting rate is initially required to produce the same
prevalence and (approximate) intensity (CMFL, Table 4)
of infection as ONCHOSIM. However, for higher ende-
micities, and due to the action of the density-dependent
establishment of adult worms that is modelled in
EPIONCHO but not in ONCHOSIM (Table 1), a higher
biting rate is required by EPIONCHO to arrive at the
same levels of endemic infection prevalence (and inten-
sity) as ONCHOSIM.
Disentangling the relative importance of different as-
sumptions for various outcomes would require in-depth
theoretical research, which is beyond the scope of this
paper. This can be done through the development and
stepwise comparison of structurally different models of
increasing complexity and realism, similar to a previous
study on HIV elimination models [56]. To understand
which level of complexity is required to address policy
questions on control and elimination, it would also be
useful to consider the predicted frequency distributions
of mf among the host population.
Conclusion
With the eventual aim to improve the predictive accuracy
of simulation models for onchocerciasis transmission and
control, and shed more light on whether current interven-
tions are on track to achieve the time-bound elimination
goals, two modelling groups working from different meth-
odological traditions have joined forces to harmonize their
models and examine the level of agreement in their pre-
dictions. This paper focused on comparing, contrasting
and understanding the similarities and differences in
projected elimination outcomes by two independently
developed, well-established models for onchocerciasis
transmission, ONCHOSIM and EPIONCHO. Predicting
eventual achievement of elimination is a challenge in infec-
tious disease modelling, and possibly even more so when it
concerns neglected tropical diseases, because of a general
lack of long-term empirical data on the outcome of interest
and gaps in knowledge on influential key population-
biological parameters. This makes cross-validation between
models particularly relevant: converging results help to
build trust in predictions, while deviations trigger investi-
gation into the causes and re-evaluation of available evi-
dence which helps to improve model quality. Transparency
is required and following “good modelling practice” [57]
we provide complete access to the models, with the neces-
sary documentation.
For this first model comparison, we have used a limited
set of hypothetical scenarios regarding epidemiological fea-
tures (initial endemicity, mf prevalence, CMFL and vector
biting rates), ranging from mesoendemic to holoendemic
onchocerciasis. As was to be expected, this revealed several
differences in model predictions, in spite of harmonization
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of some key parameters. We identified several explanations
for the differences, which will be further explored to help
to understand strengths and weaknesses of the different
modelling approaches and to help to reach consensus on
predicted timeframes and optimum interventions for the
elimination of onchocerciasis in Africa.
Our next steps using EPIONCHO and ONCHOSIM
will include testing model-predicted trends with observed
trends in infection during mass treatment, elucidating the
differences between the pOTTIS and the transmission
breakpoints, refining operational guidance to programme
managers based on these results, and identifying APOC
projects where elimination goals can be achieved with
current strategies and where adjusted, alternative, or
complementary interventions are required.
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